Demographics and disease characteristics of patients in long term follow up SVR Registry Resistance Registry N = 487 N = 114 Age, years (range) 53 (20–76) 54 (28–67) Male, n (%) 286 (59) 93 (82) Cirrhosis, n (%) 85 (18) 41 (36) Treatment Experienced, n (%) 91 (19) 49 (43) IL28B Genotype, n (%)     CC 175 (36) 38 (33) CT 244 (50) 60 (53) TT 68 (14) 16 (14) Y WU,1 M WELTMAN,1 GD ESLICK2 1Department of Gastroenterology and Hepatology, Nepean Hospital, Sydney, NSW, Australia, 2Discipline of Surgery, The University of Sydney, Sydney Medical School, Sydney, NSW, Australia Background: Transient elastography (TE) is a noninvasive and well-validated

method for measurement of liver stiffness in patients with chronic Hepatitis C. Aim: In the previous era of interferon-based therapy, studies have shown a strong association EPZ-6438 cell line between Sustained Virological Response (SVR) and improvement in Liver stiffness (LS).1 Our current study aims to explore the

kinetics of liver stiffness in Australian patients receiving hepatitis C treatment including protease inhibitors, an area not examined previously. Method: Consecutive patients at Nepean Hospital treated for Hepatitis C from 2011 onwards were included in the study. Patients were treated according to standard of care for their respective Alvelestat cell line genotypes, which included protease inhibitors in patients with Genotype 1. The patient’s initial LS measurement was taken prior to their treatment and a second measurement was made at an interval

at least 12 weeks after the end of their treatment. Other patient factors 上海皓元医药股份有限公司 such as gender, age, presence or absence of cirrhosis, alcoholism and blood tests were also collated. Results: Of the 25 patients that were included in the study, 17 (68%) patients achieved SVR. Overall, 14 (56%) patients were treated with protease inhibitors. The mean intra-patient change relative to baseline at the follow-up elastography was −4.17 kPa in the patient group who achieved SVR, vs +0.49 kPa in the patients who did not achieve an SVR (p = 0.0056). In uni-variate analysis (Mann-Whitney U test), other parameters such as protease inhibitor use, viral genotype, treatment experience, gender, age, alcohol intake and presence of cirrhosis were not predictive of LS improvement. Similarly, viral load and ALT measurement at the start of treatment didn’t reveal any significant relationship with post-treatment LS during Logistic regression. Conclusion: Measurement of liver stiffness with TE after hepatitis C treatment shows that achieving an SVR is the only statistically significant determinant associated with improvement in liver stiffness compared to baseline. Our study is one of the first to include patients treated with protease inhibitors. 1. Andersen ES, Moessner BK, Christensen PB, Kjær M, Krarup H, Lillevang S, Weis N. Lower liver stiffness in patients with sustained virological response 4 years after treatment for chronic hepatitis C.